Thrombogenesis and fibrinolysis in acute coronary syndromes. Important facets of a prothrombotic or hypercoagulable state?

Journal of the American College of Cardiology

Volumn 36, Issue 7, 2000, Pages 2044-2046

  Lip, Gregory Y H ^a   Blann, Andrew D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX;

ATHEROGENESIS; BLOOD CLOTTING; BLOOD RHEOLOGY; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; ENDOTHELIUM; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEART MUSCLE ISCHEMIA; HELICOBACTER PYLORI; HYPERCOAGULABILITY; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOCYTE FUNCTION; THROMBOGENESIS;

EID: 0033667401     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)01028-7     Document Type: Editorial

References (30)

1. Phlogose and thrombose in gerasssystem
2. Does hypertension confer a prothrombotic state? Virchow's triad revisited
3. The role of rheology and haemostatic factors in hypertension
4. Does atrial fibrillation confer a hypercoagulable state?
5. Does heart failure confer a hypercoagulable state? Virchow's triad revisited
6. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease
7. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
8. Are plasma markers of platelet, endothelial and hemostatic function related to conventional measures of cardiovascular risk in hypertensives?
9. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension
10. Fibrin D-dimer: A useful clinical marker of thrombogenesis?
11. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly study
12. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
13. Increased fibrin turnover and high PAI-1 activity as predictors of ischaemic events in atherosclerosis patients
14. Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina. In-hospital course and relationship with recurrent angina at rest
15. Serial thrombolysis-related changes after thrombolytic therapy with tPA in patients with acute myocardial infarction
16. Relation of plasma D-dimer concentrations to coronary artery reperfusion before and after thrombolytic treatment in patients with acute myocardial infarction
17. Normal and fibrinaemic patient plasma contain high molecular weight cross-linked fibrin(ogen) derivatives with intact fibrinopeptide A
18. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction
19. Plasma fibrinogen - A major coronary risk factor
20. Cross-linked fibrin degradation products (XL-FDP) as marker of early rethrombosis in percutaneous transluminal angioplasty
21. Plasma concentrations of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men
22. Cardiovascular risk and therapeutic benefit of coronary interventions for patients with unstable angina according to the troponin T status
23. Haematological stress syndrome in atherosclerosis
24. Production of C-reactive protein and risk of coronary events in stable and unstable angina
25. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina
26. Chronic infections and coronary heart disease: Is there a link?
27. Can we treat coronary artery disease with antibiotics?
28. Elevated chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction
29. A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction
30. Cytokine mediated activation of vascular endothelium